About ProQR Therapeutics NV
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PRQR
- Previous Close: $4.00
- 50 Day Moving Average: $4.18
- 200 Day Moving Average: $5.12
- 52-Week Range: $3.55 - $8.70
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.08
- P/E Growth: 0.00
- Market Cap: $94.55M
- Outstanding Shares: 23,346,000
- Beta: 0.87
- Return on Equity: -48.21%
- Return on Assets: -41.85%
Companies Related to ProQR Therapeutics NV:
- Debt-to-Equity Ratio: 0.06%
- Current Ratio: 8.90%
- Quick Ratio: 8.90%
Earnings History for ProQR Therapeutics NV (NASDAQ:PRQR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/17/2017|| || || || || || || || |
Earnings Estimates for ProQR Therapeutics NV (NASDAQ:PRQR)
Current Year EPS Consensus Estimate: $-1.83 EPS
Next Year EPS Consensus Estimate: $-1.95 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for ProQR Therapeutics NV (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ProQR Therapeutics NV (NASDAQ:PRQR)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for ProQR Therapeutics NV (NASDAQ:PRQR)
What is ProQR Therapeutics NV's stock symbol?
ProQR Therapeutics NV trades on the NASDAQ under the ticker symbol "PRQR."
Where is ProQR Therapeutics NV's stock going? Where will ProQR Therapeutics NV's stock price be in 2017?
5 equities research analysts have issued 1 year target prices for ProQR Therapeutics NV's stock. Their forecasts range from $4.50 to $40.00. On average, they expect ProQR Therapeutics NV's stock price to reach $15.90 in the next year.
When will ProQR Therapeutics NV announce their earnings?
ProQR Therapeutics NV is scheduled to release their next quarterly earnings announcement on Friday, February, 17th 2017.
Who owns ProQR Therapeutics NV stock?
ProQR Therapeutics NV's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (9.88%), Janus Capital Management LLC (1.69%), Franklin Resources Inc. (1.33%) and FMR LLC (1.02%).
Who sold ProQR Therapeutics NV stock? Who is selling ProQR Therapeutics NV stock?
ProQR Therapeutics NV's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC.
How do I buy ProQR Therapeutics NV stock?
Shares of ProQR Therapeutics NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ProQR Therapeutics NV stock cost?
One share of ProQR Therapeutics NV stock can currently be purchased for approximately $4.05.
ProQR Therapeutics NV (NASDAQ:PRQR) Chart for Wednesday, March, 1, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart